Five-year results of post-prostatectomy patients administered a hydrogel rectal spacer implant in conjunction with dose escalated external beam radiation therapy
- 28 Downloads
This study reports on the 5-year biochemical-relapse free survival (bRFS), and late gastrointestinal (GI) and genitourinary (GU) toxicities of patients who underwent a prostatectomy and received high dose (> 72 Gy) radiation therapy with an absorbable polyethylene glycol (PEG) rectal spacer implant.
From January 2010 to October 2013, 21 radical prostatectomy patients received a PEG spacer. GI and GU toxicities were scored using the National Cancer Center Institute Common Terminology Criteria for Adverse Events v4.0 grading scheme. bRFS was tallied and segregated into risk groups according to the National Cancer Comprehensive Network (NCCN) guidelines version 1.2016. Cox regression multivariate analysis was performed to elicit disease risk factors.
The mean follow-up time was 59 months (SD 12, range 40–97). Our GI toxicities for acute, 3 months, and after 6 months are as follows: grade 0 (57%, 86%, 86%), grade 1 (43%, 14%, 14%), and grade 2 (0%, 0%, 5%). Our GU toxicities for acute, 3 months, and after 6 months are as follows: grade 0 (43%, 48%, 62%), grade 1 (48%, 43%, 24%), and grade 2 (10%, 5%, 14%). There were no late grade 3 GI/GU toxicities. The 5-year overall bRFS rate was 62.2% (95% CI 42.6–90.9%, SE 12.0%). Multivariate logistic regression analysis revealed positive surgical resection margins to be predictive (p = 0.00037) for decreased biochemical control.
Hydrogel rectal spacer implants in patients who previously had a prostatectomy is well tolerated long term with reduced incidence of GI and GU toxicities, and bRFS rates consistent with previous reports in the literature.
KeywordsPEG rectal spacer Prostate cancer Radiotherapy Post-prostatectomy Toxicity High-dose EBRT
(i) Conception and design: BML, HMM, KT; (ii) administrative support: HMM, KT; (iii) provision of study materials or patients: HMM, KT; (iv) collection and assembly of data: BML, HMM, LB, AM; (v) data analysis and interpretation: BML, HMM, LB, AM, KT; (vi) manuscript writing—original draft: BML; (vii) final approval of manuscript: all authors.
Compliance with ethical standards
A portion of the study was funded by the Medici Foundation (non-profit organization).
Conflicts of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 3.McGuire S (2015) World Cancer Report 2014. World Health Organization, International Agency for Research on Cancer, WHO press, Geneva, pp 2156–5376 (Electronic)Google Scholar
- 8.Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 70(4):1124–1129CrossRefGoogle Scholar
- 13.Song DY, Herfarth KK, Uhl M, Eble MJ, Pinkawa M, van Triest B, Kalisvaart R, Weber DC, Miralbell R, DeWeese TL, Ford EC (2013) A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: analysis of dosimetric outcomes. Int J Radiat Oncol Biol Phys 87(1):81–87CrossRefGoogle Scholar
- 15.Montoya J, Gross L, Fau-Karsh E, Karsh L (2018) How I Do It: Hydrogel spacer placement in men scheduled to undergo prostate radiotherapy. Can J Urol 25(2):9288–9293Google Scholar
- 16.Mariados N, Sylvester J, Shah D, Karsh L, Hudes R, Beyer D, Kurtzman S, Bogart J, Hsi RA, Kos M, Ellis R, Logsdon M, Zimberg S, Forsythe K, Zhang H, Soffen E, Francke P, Mantz C, Rossi P, DeWeese T, Hamstra DA, Bosch W, Gay H, Michalski J (2015) Hydrogel spacer prospective multicenter randomized controlled pivotal trial: Dosimetric and clinical effects of perirectal spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 92(5):971–977CrossRefGoogle Scholar
- 17.Wilder RB, Barme GA, Gilbert RF, Holevas RE, Kobashi LI, Reed RR, Solomon RS, Walter NL, Chittenden L, Mesa AV, Agustin JK, Lizarde J, Macedo JC, Ravera J, Tokita KM (2011) Cross-linked hyaluronan gel improves the quality of life of prostate cancer patients undergoing radiotherapy. Brachytherapy 10(1):44–50CrossRefGoogle Scholar
- 18.Yeh J, Lehrich B, Tran C, Mesa A, Baghdassarian R, Yoshida J, Torrey R, Gazzaniga M, Weinberg A, Chalfin S, Ravera J, Tokita K (2016) Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy 15(3):283–287CrossRefGoogle Scholar
- 19.Yeh J, Lehrich B, Mesa A, Tran C, Barnes L, Long C, Yoshida J, Torrey R, Gazzaniga M, Albert S, Weinberg A, Alavi A, Baghdassarian R, Chalfin S, Ravera J, Tokita K (2017) Three-year outcomes of 324 prostate carcinoma patients treated with combination high-dose-rate brachytherapy and intensity modulated radiation therapy. Transl Cancer Res 6(2):269–274CrossRefGoogle Scholar
- 21.Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25(15):2035–2041CrossRefGoogle Scholar
- 24.Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A (2003) Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57(4):929–943CrossRefGoogle Scholar
- 26.Alongi F, Fiorino C, Cozzarini C, Broggi S, Perna L, Cattaneo GM, Calandrino R, di Muzio N (2009) IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. Radiother Oncol 93(2):207–212CrossRefGoogle Scholar
- 29.Ost P, Lumen N, Goessaert AS, Fonteyne V, de Troyer B, Jacobs F, de Meerleer G (2011) High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol 60(4):842–849CrossRefGoogle Scholar
- 34.Mahal BA, Ziehr DR, Hyatt AS, Neubauer-Sugar EH, O'Farrell DA, O'Leary MP, Steele GS, Niedermayr TR, Beard CJ, Martin NE, Orio PF, D'Amico AV, Devlin PM, Nguyen PL (2014) Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: initial experience and short-term results. Brachytherapy 13(5):442–449CrossRefGoogle Scholar